Sabar Karimah Es 4

4 · CAPRICOR THERAPEUTICS, INC. · Filed Apr 1, 2026

AI-generated summary of this filing

Updated Apr 2, 2026

Capricor (CAPR) Director Sabar Karimah Es Exercises Options, Sells Shares

What Happened

Director Sabar Karimah Es exercised a total of 115,000 option shares (61,265 on 2026-03-31 and 53,735 on 2026-04-01) at $4.86 per share and then sold those same shares in the open market. The sales generated gross proceeds of approximately $3,515,468; the aggregate exercise cost was $558,900, leaving about $2,956,568 before taxes and fees. The sales were executed under a pre-established 10b5-1 trading plan.

Key Details

Transaction dates and prices:
- 2026-03-31: Exercised 61,265 shares @ $4.86 (cost $297,748); sold 61,265 shares @ weighted avg $30.17 (gross $1,848,243). (Sale prices ranged $30.00–$30.46.)
- 2026-04-01: Exercised 53,735 shares @ $4.86 (cost $261,152); sold 53,735 shares @ weighted avg $31.03 (gross $1,667,225). (Sale prices ranged $30.28–$31.39.)
Total exercised: 115,000 shares; total gross sale proceeds ≈ $3.52M; total exercise cost ≈ $558.9k; proceeds minus exercise cost ≈ $2.96M (pre-tax, pre-fees).
Shares owned after the transactions are not specified in the provided filing.
Footnotes of note:
- Sales were made pursuant to a 10b5-1 trading plan adopted by the reporting person in December 2025.
- Weighted-average sale prices and price ranges are provided in the filing (see above).
- Vesting: original award vested 25% on Aug 1, 2022, with the remainder vesting monthly thereafter (1/36 per month).
- The filing shows the derivative instruments were converted/exercised (reported as dispositions of the derivative and acquisitions of common stock).
Filing timeliness: Form 4 was filed 2026-04-01 for transactions on 2026-03-31 and 2026-04-01; this appears timely under Form 4 reporting rules.

Context

This was an option exercise followed by immediate sale of the acquired shares (commonly a cashless exercise pattern). The use of a 10b5-1 plan indicates the sales were pre-arranged, which is common for officers/directors to avoid trading-rule timing issues. These transactions are factual disclosures and do not, by themselves, indicate the director’s ongoing view of the company.

Form 4

Period: 2026-03-31

Director

Transactions

Exercise/Conversion
Common Stock
2026-03-31$4.86/sh+61,265$297,748→ 61,265 total
Sale
Common Stock
[F1][F2]
2026-03-31$30.17/sh−61,265$1,848,243→ 0 total
Exercise/Conversion
Common Stock
2026-04-01$4.86/sh+53,735$261,152→ 53,735 total
Sale
Common Stock
[F1][F3]
2026-04-01$31.03/sh−53,735$1,667,225→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
[F4]
2026-03-31−61,265→ 53,735 total
Exercise: $4.86Exp: 2031-07-23→ Common Stock (61,265 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F4]
2026-04-01−53,735→ 0 total
Exercise: $4.86Exp: 2031-07-23→ Common Stock (53,735 underlying)

Footnotes (4)

[F1]Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
[F2]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.46, inclusive.
[F3]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.28 to $31.39, inclusive.
[F4]Shares vested 25% on August 1, 2022 with the remainder vesting 1/36 per month commencing September 1, 2022.

Signature

/s/ Linda Marban, Attorney-in-Fact|2026-04-01

1 file